Colorectal Surgeon Dr. Julio Garcia-Aguilar, MD, PhD (seated) with nurse Kieran Kelleher BSN-RN. Dr. Garcia-Aguilar and the colorectal service at MSK are experts at the watch and wait approach to ...
Total neoadjuvant treatment (TNT) may offer a promising alternative to surgery for patients with stage I rectal cancer (S1RC), a small study finds. 1 Among patients treated, TNT achieved a 93.7% ...
The Brighterside of News on MSN
Groundbreaking clinical trial cures cancer in 100% of patients
In a clinical trial involving 14 participants, immunotherapy on its own effectively eradicated rectal cancer. This ...
New cancer research pioneered by Memorial Sloan Kettering points to a strong alternative to chemotherapy, surgery and radiation for some forms of cancer. Nearly 80% of patients who suffered from a ...
More young adults are also being diagnosed, according to Yale Medicine and the Cancer Research Institute. According to the ...
Neoadjuvant treatment with a programmed cell death 1 (PD-1) inhibitor induces clinical complete response and leads to organ preservation in a high proportion of patients with early-stage, mismatch ...
Dr. Joshua Sabari sat down with Dr. Michael Cecchini to discuss advances in colorectal cancer management and key data ...
A retrospective study of patients with distal rectal cancer at Memorial Sloan Kettering Cancer Center (MSK) has found a higher rate of local recurrence after intersphincteric resection with handsewn ...
Use of a neoadjuvant checkpoint inhibitor enabled a high proportion of patients with early-stage mismatch repair-deficient (dMMR) solid tumors to avoid surgery and achieve organ preservation in a ...
Dostarlimab treatment led to complete clinical responses in 82% of patients with dMMR tumors, avoiding surgery for most. Recurrence-free survival at two years was 92%, with a median follow-up of 20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback